denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Session: 613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster I
Hematology Disease Topics & Pathways:
Research, Clinical trials, Lymphoid Leukemias, ALL, Clinical Research, Diseases, Lymphoid Malignancies
Methods: Pts with R/R B-ALL could receive 1‒5 cycles of SC blinatumomab as monotherapy. Transplantation after the end of the 1st cycle was permitted. Each cycle included a 26-day treatment period and a 1-week treatment-free interval. Blinatumomab was given at two doses, either 1) 250μg once-daily (QD) for week 1 and 500μg three times weekly (TIW) thereafter (250μg/500μg) or 2) 500μg QD for week 1 and 1000μg TIW thereafter (500μg/1000μg). The primary efficacy end point was complete remission (CR) or CR with partial hematologic recovery (CRh) within two cycles. Pts with incomplete hematology recovery (CRi) were included in the analysis. Duration of CR/CRh/CRi was defined from initial remission until relapse or latest disease assessment.
Results: At the data cut-off on May 9, 2024, 27 pts were treated with SC blinatumomab and had opportunity to be observed in long term follow up; 14 at 250µg/500µg and 13 at 500µg/1000µg. Sixteen pts (59%) were male, median age was 52 years (range, 19‒78) with 12 pts (44%) ≥ 55 years. For race/ethnicity, 19 pts were white, 1 pt was Asian, 0 pts were Black, 7 pts reported other race, and 13 pts reported Hispanic ethnicity. Pts had received a median of 2 (range, 1‒5) prior lines of therapy. Of these, 9 pts (33%) were primary refractory, 8 pts (30%) had relapsed after prior HSCT, 4 pts (15%) had relapsed after prior CD19 CAR T–cell therapy, 7 pts (26%) had prior inotuzumab ozogamycin, and 5 pts (19%) had previously received cIV blinatumomab. Median bone marrow blast percentage was 74% (range, 5%‒98%). Median number of SC blinatumomab cycles received was 2 (range, 1‒5).
Of the 27 pts, 24 (89%) achieved a remission (CR/CRh/CRi) within 2 cycles; 12 of 14 (86%) at 250μg/500μg and 12 of 13 (92%) at 500μg/1000μg. Ten (83%) and 12 (100%) responders in 250µg/500µg and 500µg/1000µg, respectively, were negative for measurable residual disease (MRD; <10-4). Three pts did not have response evaluation – 2 due to fatal adverse events, unrelated to SC blinatumomab, and 1 pt requested to discontinue treatment. Median duration of remission was not reached for either dose. The median (range) follow-up was 5.0 (0.49–10.9) months overall, and 4.2 (0.66–10.6) and 5.8 (0.49–10.9) months for 250μg/500μg and 500μg/1000μg, respectively. Of the 24 pts in remission, 21 (88%) have not relapsed. Median (range) of follow-up in CR without relapse (n = 16) was 5.2 (0.66–10.9) months overall, and 4.4 (0.66–10.6) and 5.8 (0.49–10.9) months for 250μg/500μg and 500μg/1000μg, respectively. Three pts relapsed (2 in 500μg/1000μg had CD19 negative relapse [1 each after cycle 2 and HSCT] and 1 pt in 250μg/500μg after early discontinuation) with a median duration of CR/CRh/CRi of 3.8 (range, 1.8–8.4) months.
At data cut off, 19 pts were alive with median (range) follow-up for overall survival (OS) of 9.8 (6.5–14.3) months – dose groups follow-up was 9.8 (6.5–13.8) months for 250μg/500μg and 9.8 (8.0 – 14.3) months for 500μg/1000μg. Five pts died, all in the 250μg/500μg group, one of which had relapsed, with a median time to death of 6.3 (range, 4.7–14.5) months. Eleven (46%) pts received HSCT after responding to SC blinatumomab; 5 (42%) and 6 (50%) for 250μg/500μg and 500μg/1000μg, respectively. Nine remain alive (3 and 6 in 250μg/500μg and 500μg/1000μg, respectively), with 2 pts in 500μg/1000μg receiving HSCT and experiencing relapse. Two pts from 250μg/500μg died in CR after HSCT. Six of 12 responders (median OS of 9.8 months [range, 8.0 – 14.3]) treated with 500μg/1000μg received SC blinatumomab without proceeding to HSCT; 5 completed ≥4 cycles of SC blinatumomab. All 6 are alive and in CR.
Conclusion: Treatment with SC blinatumomab in heavily pretreated pts with R/R B-ALL resulted in high response rates, demonstrated deep and durable remission, and OS. The trial continues to accrue. These results warrant further evaluation of SC blinatumomab.
Jabbour et al. Am J Hematol. 2024: 99(4):586-595.
Disclosures: Jabbour: AbbVie, Adaptive Biotechnologies, Amgen, Astellas Pharma, BMS, Genentech, Incyte, Pfizer, Takeda: Consultancy; AbbVie, Adaptive Biotechnologies, Amgen, Ascentage Pharma Group, Pfizer, Takeda: Research Funding. Zugmaier: Amgen: Current Employment, Current equity holder in publicly-traded company, Patents & Royalties: WO2010/052014, WO2010/052013, WO2011/051307, WO2012/055961, WO2012/062596, WO2014/122251, WO2015/181683, WO2016/184931, and WO/2023/062188. Martinez Sanchez: Jazz Pharmaceuticals, AbbVie, Pfizer, BMS: Other: Travel grant. Rifon: Amgen: Honoraria, Other: Travel grant. Cassaday: Amgen: Honoraria, Research Funding; Kite/Gilead, Incyte, Pfizer, Merck, Servier, Vanda Pharmaceuticals: Research Funding; Pfizer, Kite/Gilead, Autolus, Jazz: Consultancy; Pfizer, Kite/Gilead: Honoraria; Pfizer: Other: Travel grant for attending meetings; Autolus, Pepro-Mene Bio: Other: Advisory board; Seagen: Current equity holder in publicly-traded company. Cluzeau: Takeda: Speakers Bureau; BMS: Consultancy, Speakers Bureau; Jazz Pharma: Consultancy, Research Funding, Speakers Bureau; Novartis: Consultancy, Speakers Bureau; Amgen: Speakers Bureau; Syros: Speakers Bureau; Servier: Consultancy, Speakers Bureau; Keros: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Abbvie: Consultancy, Research Funding, Speakers Bureau; Incyte: Speakers Bureau; Pfizer: Other: International Congress. Huguet: Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Incyte Biosciences: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Pfizer: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Vucinic: Amgen: Honoraria, Other: Travel grant; Gilead/Kite, Janssen, BMS Celgene, Novartis: Consultancy, Honoraria. Böll: Amgen, Kite/Gilead, MSD, Miltenyi, Noscendo, Novartis, Pfizer, Celgene, Astellas, J&J: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding. Rijneveld: Vertex: Other: Advisory board. Tormo: SOBI: Other: Data Safety Monitoring Board; Janssen, AbbVie, Jazz: Other: Travel grant for attending meetings; AbbVie, Gilead, Pfizer, Astellas, BMS: Honoraria. Abdul-Hay: Amgen, Incyte, Novartis, Takeda, Daiichi, Kite: Other: Advisory board; Amgen: Membership on an entity's Board of Directors or advisory committees, Other: Advisory Board ; Incyte: Membership on an entity's Board of Directors or advisory committees, Other: Advisory Board; Novartis: Membership on an entity's Board of Directors or advisory committees, Other: Advisory Board; Takeda: Membership on an entity's Board of Directors or advisory committees, Other: Advisory Board ; Daiichi: Membership on an entity's Board of Directors or advisory committees, Other: Advisory Board; Kite: Membership on an entity's Board of Directors or advisory committees, Other: Advisory Board ; PureTech: Consultancy, Other: Consultant; Abbvie: Consultancy, Other: Consultant . Gordon: Amgen: Current Employment, Current equity holder in publicly-traded company. Rambaldi: Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Speakers Bureau; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Speakers Bureau; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Speakers Bureau; Jazz: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Speakers Bureau; Astellas: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Speakers Bureau; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Speakers Bureau; Incyte: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Speakers Bureau; Kite-Gilead: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Speakers Bureau; Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Speakers Bureau; Omeros: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Speakers Bureau. Kantarjian: AbbVie, Amgen, Ascentage, Ipsen Biopharmaceuticals, KAHR Medical, Novartis, Pfizer, Shenzhen Target Rx, Stemline,Takeda: Consultancy, Honoraria.
OffLabel Disclosure: Blinatumomab is a bispecific T-cell engager molecule that is indicated for treatment of CD19-positive B-cell precursor ALL and administered as a continuous IV infusion. This study investigates subcutaneous administration.